Patients with relapsed or refractory B‐ALL in Hebei Second Provincial People Hospital were recruited in the phase I/II clinical trial of CD19 CAR‐T cell treatment (NCT02963038). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.